Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Pathogenesis of HIV in the central nervous system.

Valcour V, Sithinamsuwan P, Letendre S, Ances B.

Curr HIV/AIDS Rep. 2011 Mar;8(1):54-61. doi: 10.1007/s11904-010-0070-4. Review.

2.

Current understanding of HIV-associated neurocognitive disorders pathogenesis.

Gannon P, Khan MZ, Kolson DL.

Curr Opin Neurol. 2011 Jun;24(3):275-83. doi: 10.1097/WCO.0b013e32834695fb. Review.

3.

HIV-associated neurological disorders: a guide to pharmacotherapy.

Tan IL, McArthur JC.

CNS Drugs. 2012 Feb 1;26(2):123-34. doi: 10.2165/11597770-000000000-00000. Review.

PMID:
22201342
4.

Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.

Peluso MJ, Spudich S.

Curr HIV/AIDS Rep. 2014 Sep;11(3):353-62. doi: 10.1007/s11904-014-0223-y.

PMID:
25063356
5.

Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.

Cysique LA, Brew BJ.

Neuropsychol Rev. 2009 Jun;19(2):169-85. doi: 10.1007/s11065-009-9092-3. Epub 2009 May 9. Review.

PMID:
19424802
6.

Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.

Bogoch II, Davis BT, Venna N.

J Infect. 2011 Sep;63(3):236-9. doi: 10.1016/j.jinf.2011.05.011. Epub 2011 May 25.

PMID:
21658774
7.

HIV pharmacology: barriers to the eradication of HIV from the CNS.

McGee B, Smith N, Aweeka F.

HIV Clin Trials. 2006 May-Jun;7(3):142-53. Review.

PMID:
16880170
8.

HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.

Chan P, Brew BJ.

Curr HIV/AIDS Rep. 2014 Sep;11(3):317-24. doi: 10.1007/s11904-014-0221-0. Review.

PMID:
24966139
9.

HIV, antiretroviral therapies, and the brain.

Liner KJ 2nd, Ro MJ, Robertson KR.

Curr HIV/AIDS Rep. 2010 May;7(2):85-91. doi: 10.1007/s11904-010-0042-8. Review.

PMID:
20425562
10.

Combination antiretroviral therapy modulates the blood oxygen level-dependent amplitude in human immunodeficiency virus-seropositive patients.

Ances BM, Roc AC, Korczykowski M, Wolf RL, Kolson DL.

J Neurovirol. 2008 Oct;14(5):418-24. doi: 10.1080/13550280802298112.

11.

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.

Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I; CHARTER Group; HNRC Group.

J Neurovirol. 2011 Feb;17(1):3-16. doi: 10.1007/s13365-010-0006-1. Epub 2010 Dec 21.

13.
14.

Neurocognitive impairment and neuroCART.

Wright E.

Curr Opin HIV AIDS. 2011 Jul;6(4):303-8. doi: 10.1097/COH.0b013e3283477c46. Review.

PMID:
21546833
15.

Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system.

Nath A, Sacktor N.

Curr Opin Neurol. 2006 Aug;19(4):358-61. Review.

PMID:
16914973
16.

Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications.

Hong S, Banks WA.

Brain Behav Immun. 2015 Mar;45:1-12. doi: 10.1016/j.bbi.2014.10.008. Epub 2014 Oct 22. Review.

PMID:
25449672
17.

HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment.

Spudich S, González-Scarano F.

Cold Spring Harb Perspect Med. 2012 Jun;2(6):a007120. doi: 10.1101/cshperspect.a007120. Review.

18.

HIV-associated neurocognitive disorders: perspective on management strategies.

Nabha L, Duong L, Timpone J.

Drugs. 2013 Jun;73(9):893-905. doi: 10.1007/s40265-013-0059-6. Review.

19.

Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.

Taiwo B, Hicks C, Eron J.

J Antimicrob Chemother. 2010 Jun;65(6):1100-7. doi: 10.1093/jac/dkq096. Epub 2010 Mar 25. Review.

20.

HIV-1-associated central nervous system dysfunction.

Krebs FC, Ross H, McAllister J, Wigdahl B.

Adv Pharmacol. 2000;49:315-85. Review.

PMID:
11013768
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk